13 Best Fortune 500 Dividend Stocks to Invest In

Page 9 of 11

3. Merck & Co., Inc. (NYSE:MRK)

% Dividend Yield: 4.00%

Merck & Co., Inc. (NYSE:MRK) gains an entry into our list of 13 best Fortune 500 dividend stocks to invest in. Following a decline in revenue in the second quarter of 2025, the company received the FDA approval for KEYTRUDA QLEX™ injection.

Merck & Co., Inc. (NYSE:MRK) reported an Adjusted EPS of $2.13 for the second quarter of 2025. The reported value surpasses the $2.03 consensus, projecting a positive perception towards its operational efficiency. However, worldwide sales of $15.8 billion slightly missed expectations and declined 2% year-over-year. The decline was attributed to a drop in Gardasil sales in China. Meanwhile, the sales of the blockbuster oncology drug KEYTRUDA surged by 9% to $8.0 billion.

Additionally, on September 19, 2025, the company announced receiving the U.S. FDA approval for KEYTRUDA QLEX™ injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA. Dr. J. Thaddeus Beck, oncologist and Medical Director of the Highlands’ Clinical Trials Office, made the following statement with respect to the approval.

“This approval is significant for patients and health care providers like me who have been using immunotherapies for years to treat certain cancers”

Supported by the new approvals, the company further attracts investor interest by offering a dividend yield of 4%.

Merck & Co., Inc. (NYSE:MRK) is a global healthcare company specializing in the development and production of prescription medicines, vaccines, and animal health products. Founded in 1891, the company is known for its research-driven approach to tackling some of the world’s most challenging diseases. It operates from its headquarters located in New Jersey.

Page 9 of 11